Source: Gelonghui

In the field of medical technology investment, a growing consensus is that simply identifying significant unmet clinical needs is no longer sufficient to constitute a solid investment rationale. The real watershed that determines a company's long-term value lies in whether it has built a closed-loop capability to systematically solve that problem.

Nowadays, with the widespread adoption of low-dose CT scans, the challenge of early lung cancer screening has shifted from the difficulty of detecting lung nodules to the gap in diagnostic capabilities. Especially for small peripheral lung nodules, which account for a significant proportion and have complex anatomical structures, achieving stable intervention and high-precision localization of the lesions has become a key variable restricting diagnostic and treatment effectiveness.

At this juncture of shifting capital logic, Noah Medical, as an innovator in the field of natural cavity surgical robots, has not only accurately addressed core clinical gaps with its technology system built around "arrival + positioning," but also taken a differentiated path from single-point breakthroughs to platform extension, with medical value creation at its core.

By focusing on both "arrival and location," we can address the shortcomings in the diagnosis process.

Traditional bronchoscopy faces two fundamental challenges when dealing with peripheral pulmonary nodules: first, whether the instrument can stably reach lesions in the distal lung; and second, whether the location of the lesion can be accurately confirmed in a dynamic environment to perform a biopsy.

These two problems cannot be solved by optimizing the efficiency of existing processes; rather, they require building entirely new technological capabilities. Noah Medical's core technological strategy revolves around these two points.

Noah Medical has achieved a deep integration of its disposable robotic flexible endoscope with a real-time image positioning system in building the capability to "stablely reach the lesion".

Its core product, the Galaxy platform, features a robotic flexible endoscope with an ultra-thin 4.0mm outer diameter, allowing for 180-degree omnidirectional bending. This enables it to easily navigate the complex, tree-like branching structures of the lungs, achieving full lung coverage and solving the problem of blind spots in reaching distant lung lesions. Furthermore, its disposable design eliminates the risk of cross-infection from reuse, a key factor supporting its clinical safety.

In the stage of "high-precision confirmation of lesion location", real-time image positioning technology provides a targeted solution.

The deviation between preoperative CT images and the actual anatomical structure of the human body during surgery (i.e., CT-to-body divergence) is the main cause of localization errors, which is influenced by a variety of dynamic factors such as the patient's breathing status and changes in body position.

3D Imaging DT, a proprietary tomographic synthesis technology, utilizes a two-dimensional C-arm (such as a traditional C-arm, mobile CBCT, or fixed CBCT) to achieve three-dimensional reconstruction. Through real-time image fusion and dynamic correction capabilities, it updates the lesion location intraoperatively and dynamically corrects deviations, ensuring high-precision entry of the instrument into the lesion. Simultaneously, its built-in enhanced fluoroscopy and StrikePoint functions enable the overlay display of lesions invisible under two-dimensional fluoroscopy and can quantitatively calculate the distance to the lesion center, further improving positioning accuracy.

Of course, clinical data serves as direct evidence of technical capabilities.

To date, the Galaxy system has completed more than 10,000 surgeries. In the post-marketing clinical study (MATCH 2 Study) in the United States in 2025, the navigation and biopsy success rate reached 100%, the proportion of the tool in the lesion was consistent with the CT image at 96.7%, the strict diagnostic rate was as high as 96.7%, and the incidence of pneumothorax was only 3%, with no serious adverse events.

Research at the Cleveland Clinic further shows that its tools achieve a 98% accuracy rate within the lesion and a 95% diagnostic accuracy rate. Even with smaller nodule sizes, it can still maintain a high diagnostic rate, fully demonstrating the stability and reliability of its dual-core "arrival + localization" capabilities.

It can be said that this capability is not a simple optimization of the existing diagnosis and treatment process, but rather a fundamental solution that addresses the core shortcomings in the diagnosis process, making it a typical "medical value creation" solution.

High-precision positioning integrates diagnosis and treatment, opening up long-term potential for the platform.

When stable, repeatable, and real-time tumor localization capabilities are achieved, the foundation for a comprehensive reconstruction of the lung cancer diagnosis and treatment model will be laid.

In traditional lung cancer diagnosis and treatment, the process often involves multiple steps, requiring patients to undergo multiple surgeries. This not only increases pain and financial burden but also raises the risk of complications.

Noah Medical's technology system allows patients to complete the diagnosis and treatment of lung nodules in a single surgery, without any incisions or bleeding. Patients can be discharged on the same day or the next day after the surgery, leaving no scars. This significantly improves the efficiency, safety, and patient experience of diagnosis and treatment.

The core of this integrated diagnosis and treatment lies in the design of its technological system. The Galaxy platform, through its integrated design of the working channel and operating system, ensures instrument accessibility while maintaining operational space and visual stability, thus achieving full intraoperative visualization and supporting multi-step operations. Building upon this, the controller integrates irrigation and suction functions, coupled with high-precision real-time positioning capabilities, enabling physicians to complete procedures such as biopsy and ablation within a single surgery, achieving a closed loop of "diagnosis as treatment."

From a clinical perspective, this not only reduces the cost and trauma of diagnosis and treatment for patients, but also seizes the golden window for early treatment of lung cancer, improving patient survival rates. From a commercial perspective, non-invasive early diagnosis of lung cancer provides a safe diagnostic solution for more people diagnosed with lung nodules. The integration of diagnosis and treatment also expands the application scenarios of the product, adds a closed loop to non-invasive treatment, and enhances the clinical value and commercial returns of a single device.

More noteworthy is that Noah Medical's value proposition extends beyond its success in the single market of lung cancer diagnosis. The underlying logic of its technological system lies in the construction of natural cavities as a common pathway, possessing inherent potential for cross-departmental expansion.

The human digestive tract, urinary system, and other systems also present numerous complex scenarios requiring high-precision intervention. Noah Medical's technology system, built around flexible access, real-time image positioning, non-invasive diagnosis and treatment, and surgery, has been fully validated in the lungs, and its path to platform replication to other natural cavity departments is clearly visible.

This is precisely where the strategic value of platform companies lies compared to single-product companies.

Currently, the company has clarified its R&D path. In the short term, it will deepen the functional upgrade of the bronchoscopy robot. In the medium term, it will expand into adjacent cavity fields such as digestive tract and urology robots. In the long term, it plans to create "digital AI non-invasive intelligent diagnosis and treatment" to achieve the integration of robot AI system with intraoperative imaging, vital sign monitoring and other equipment.

Conclusion

The key to evaluating Noah Medical goes beyond simply predicting whether it can gain a foothold in the field of lung cancer diagnosis. The real core lies in understanding whether it has built a technological system capable of solving clinical challenges, and whether this system possesses the platform potential to deliver value to a wider audience.

From an investment perspective, its core value lies in three points: First, it enters the high-value track of early lung cancer diagnosis, solving real and challenging clinical problems with strong demand certainty; second, its technology system built around "arrival + positioning" fills the core gaps in the diagnostic process, forming an integrated diagnosis and treatment closed loop, which is a "capability-creating" innovation with high technological barriers; third, based on the reusability of natural cavities, it opens up cross-departmental platform development space, with significant long-term growth potential.

Undeniably, Noah Medical is standing at the starting point of a new round of value discovery.

This article was originally published on Gelonghui and is reprinted with permission from Tianjin Puli Ark Medical Technology Co., Ltd. Copyright belongs to the original author. Please contact the original source for reprint permission. This article does not constitute medical advice; please consult your doctor for specific diagnosis and treatment.

Disclaimer: The content on this platform is for academic exchange among medical professionals only and does not constitute any medical advice. Patients with medical needs should consult a doctor for professional guidance. The technical opinions of medical professionals published on this platform do not represent the position of this company.

Copyright of all content in this article belongs to Puli Ark. Unauthorized reproduction or adaptation in any form is prohibited. Our company assumes no responsibility for any losses caused by improper reproduction or citation of this article and reserves the right to pursue legal action against infringers.